Biologics

AorTech enters orthopaedic market

Biomaterials and medical device development firm AorTech has entered the orthopaedic market following a polymer licence and manufacturing deal.

AorTech said it had reached a non-exclusive licensing agreement for the first use of its Elast-Eon polymers in a next generation orthopaedic implant with a leading multi-national orthopaedic firm.

The device is in late stage development and uses AorTech’s proprietary reaction injection moulding (RIM) technology.

Clinical trials are expected to begin sometime in the third quarter.

AorTech CEO Frank Maguire said: “This co-development project is one of several we currently have under way with both large and early stage orthopaedic device firms.

“These programmes encompass a spectrum of device design platforms including lumbar, cervical and thoracic spine, hip, knee and intramedullary nail devices.

“All of these co-development projects are leveraging both our best-in-class soft biostable polymer materials along with our proprietary small part RIM technology.

“The outstanding metal to polymer and polymer to polymer bonds we are achieving with the utilisation of RIM are providing design options for implantable orthopaedic device teams that were previously not possible.”

The transaction includes licensing fees in the form of up front and milestone payments along with provisions for polymer and manufactured component sales.

Read the Rest Here

Print Friendly, PDF & Email
Tags

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button
Close